AOD-9604 6MG + CJC-1295 + 3MG + Ipamorelin 3MG

Name: AOD-9604 6MG + CJC-1295 + 3MG + Ipamorelin 3MG
SKU: 208
Availability: InStock

AOD-9604 is known for its fat-burning properties. When combined with CJC-1295 and Ipamorelin, this blend may promote lipolysis while enhancing muscle development and recovery. The synergy of these peptides could offer comprehensive benefits in body composition management. These descriptions are crafted to provide clear insights into each peptide blend’s unique properties while maintaining originality.

Product Usage

This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

What Is AOD-9604 6MG + CJC-1295 + 3MG + Ipamorelin 3MG?

This blend combines three peptides: AOD-9604, CJC-1295, and Ipamorelin. Each peptide has unique properties and potential effects on the body. AOD-9604 is a modified fragment of human growth hormone (HGH) designed to retain fat-burning properties without stimulating IGF-1 production. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone. Ipamorelin is a selective growth hormone secretagogue and ghrelin mimetic that also promotes GH release. When combined, these peptides are believed to offer synergistic effects, particularly in areas of fat metabolism, muscle growth, and overall rejuvenation.

Structure

Research Findings

Fat Metabolism: AOD-9604 has shown potential in enhancing lipolysis and inhibiting lipogenesis in animal studies, although human trials have had mixed results.
Growth Hormone Stimulation: CJC-1295 and Ipamorelin have demonstrated the ability to increase growth hormone levels, with some studies showing a 200-1000% increase in GH levels.
Muscle Growth and Recovery: The combination of CJC-1295 and Ipamorelin has shown potential in enhancing muscle cell proliferation and hypertrophy.
Synergistic Effects: The blend of these peptides is believed to offer enhanced benefits compared to their individual use, potentially providing a more comprehensive approach to body composition and metabolic health.
Safety Profile: While individual peptides have shown generally favorable safety profiles in limited studies, the long-term safety of this specific blend has not been extensively studied.

Future Research Directions

Long-term Safety Studies: Extended research is needed to evaluate the long-term effects and safety profile of this peptide blend, particularly for chronic use.
Efficacy Studies: More rigorous clinical trials are required to evaluate the potential therapeutic uses of this combination in various conditions such as obesity, muscle-wasting diseases, and age-related decline.
Optimal Dosing Regimens: Investigation into optimal delivery methods and dosing frequencies for different conditions could enhance the therapeutic potential of this peptide blend.
Mechanism of Action: Additional studies to fully elucidate the molecular mechanisms by which this peptide blend exerts its diverse effects across different tissue types are needed.
Comparative Studies: Further research comparing this blend to other growth hormone-related therapies, including direct GH administration, is warranted to establish its relative efficacy and safety.

References

Stier, H., et al. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15. [Online].
Available: https://jofem.org/index.php/jofem/article/view/157/194
Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. [Online].
Available: https://pubmed.ncbi.nlm.nih.gov/16352683/
Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. [Online].
Available: https://pubmed.ncbi.nlm.nih.gov/9849822/
Focal Point Vitality. (2024). AOD 9604 Peptide Therapy. [Online].
Available: https://focalpointvitality.com/aod-9604-peptide/
Peptide Sciences. (2024). CJC-1295, Ipamorelin 10mg (No DAC) (Peptide Blend). [Online].
Available: https://www.peptidesciences.com/cjc-1295-ipamorelin-10mg-blend

This peptide blend represents a promising avenue for research in various fields, including fat metabolism, muscle growth, and anti-aging therapies. As with all peptide combinations, it is important to use this blend under controlled research conditions, and its potential benefits and risks require ongoing evaluation through further scientific studies.

AOD-9604 6MG + CJC-1295 + 3MG + Ipamorelin 3MG

Product Usage

What Is AOD-9604 6MG + CJC-1295 + 3MG + Ipamorelin 3MG?

Structure

Research Findings

Future Research Directions

References

Related Products

CJC NO DAC 5MG / IPAMORELIN 5MG

BPC-157 5MG, TB-500 5MG (10MG Total Blend)

Tesamorelin 6MG + CJC-1295 3MG + Ipamorelin 3MG + TCI-6/3/3MG

Create Your Wholesale Account today

Site Map

Other Links

Contact Info